共 50 条
- [41] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialLANCET, 2022, 399 (10319): : 36 - 49Stuart, Arabella S., VShaw, Robert H.Liu, XinxueGreenland, MelanieAley, Parvinder K.Andrews, Nick J.Cameron, J. C.Charlton, SueClutterbuck, Elizabeth A.Collins, Andrea M.Darton, TomDinesh, TanyaDuncan, Christopher J. A.England, AnnaFaust, Saul N.Ferreira, Daniela M.Finn, AdamGoodman, Anna L.Green, Christopher A.Hallis, BassamHeath, Paul T.Hill, HelenHorsington, Bryn M.Lambe, TeresaLazarus, RajekaLibri, VincenzoLillie, Patrick J.Mujadidi, Yama F.Payne, RuthPlested, Emma L.Provstgaard-Morys, SamuelRamasamy, Maheshi N.Ramsay, MaryRead, Robert C.Robinson, HannahScreaton, Gavin R.Singh, NishaTurner, David P. J.Turner, Paul J.Vichos, IasonWhite, RachelNguyen-Van-Tam, Jonathan S.Snape, Matthew D.
- [42] Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trialVACCINE, 2020, 38 (18) : 3411 - 3421Asante, Kwaku PokuAnsong, DanielKaali, SeyramAdjei, SamuelLievens, MarcBadu, Lydia NanaDarko, Prince AgyapongBuabeng, Patrick Boakye YiadomBoahen, OwusuRettig, Theresa MariaAgutu, ClaraHarrison, Samuel Benard EkowNtiamoah, YawAnim, Japhet AdomakoAdeniji, ElishaDornudo, Albert AgordoGvozdenovic, EmiliaDosoo, DavidSambian, DavidOwusu-Boateng, HarryWilson, Elvis AtoPrempeh, FrankVandoolaeghe, PascaleSchuerman, LodeOwusu-Agyei, SethAgbenyega, TsiriOfori-Anyinam, Opokua
- [43] Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adultsLANCET MICROBE, 2022, 3 (03): : E173 - E183Ahn, Jin YoungLee, JeongsooSuh, You SukSong, Young GooChoi, Yoon-JeongLee, Kyoung HwaSeo, Sang HwanSong, MankiOh, Jong-WonKim, MinwooSeo, Han-YeongKwak, Jeong-EunYoun, Jin WonWoo, Jung WonShin, Eui-CheolSung, Young ChulPark, Su-HyungChoi, Jun Yong
- [44] A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in IndiaECLINICALMEDICINE, 2021, 42Kulkarni, Prasad S.Padmapriyadarsini, ChandrasekaranVekemans, JohanBavdekar, AshishGupta, MadhuKulkarni, PraveenGarg, B. S.Gogtay, Nithya J.Tambe, MuralidharLalwani, SanjaySingh, KiranjitMunshi, RenukaMeshram, SushantSelvavinayagam, T. S.Pandey, KrishnaBhimarasetty, Devi MadhaviRamakrishnan, S. R.Bhamare, ChetanrajDharmadhikari, AbhijeetVadakkedath, RajeevBonhomme, Cyrille J.Thakar, MadhuriKurle, Swarali N.Kelly, Elizabeth J.Gautam, ManishGupta, NiveditaPanda, SamiranBhargava, BalramShaligram, UmeshKapse, DhananjayGunale, Bhagwat
- [45] Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trialEMERGING MICROBES & INFECTIONS, 2024, 13 (01)Xu, Jia-WeiWang, Bu-SenGao, PingHuang, Hai-TaoWang, Fei-YuQiu, WeiZhang, Yuan-YuanXu, YuGou, Jin-BoYu, Lin-LingLiu, XuanWang, Rui-JieZhu, TaoHou, Li-HuaQing-Wang
- [46] Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trialLANCET INFECTIOUS DISEASES, 2022, 22 (12): : 1716 - 1727Lazarus, RajekaQuerton, BenedicteRamljak, Irena CorbicDewasthaly, ShaileshJaramillo, Juan CarlosDubischar, KatrinKrammer, MichaelWeisova, PetronelaHochreiter, RomanaEder-Lingelbach, SusanneTaucher, ChristianFinn, Adam
- [47] Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialLANCET, 2020, 396 (10249): : 479 - 488Zhu, Feng-CaiGuan, Xu-HuaLi, Yu-HuaHuang, Jian-YingJiang, TaoHou, Li-HuaLi, Jing-XinYang, Bei-FangWang, LingWang, Wen-JuanWu, Shi-PoWang, ZhaoWu, Xiao-HongXu, Jun-JieZhang, ZheJia, Si-YueWang, Bu-SenHu, YiLiu, Jing-JingZhang, JunQian, Xiao-AiLi, QiongPan, Hong-XingJiang, Hu-DachuanDeng, PengGou, Jin-BoWang, Xue-WenWang, Xing-HuanChen, Wei
- [48] Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in RussiaPLOS ONE, 2023, 18 (03):Lioznov, DmitryAmosova, Irina A.Sheetikov, SavelyZornikova, KseniaSerdyuk, YanaEfimov, GrigoryTsyferov, MikhailKhmelevskii, MikhailAfanasiev, AndreiKhomyakova, NadezhdaZubkov, DmitryTikhonov, AntonZhu, TaoBarreto, LuisDzutseva, Vitalina
- [49] Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trialLANCET INFECTIOUS DISEASES, 2024, 24 (07): : 687 - 697Dixit, AvikaBennett, RichardAli, KashifGriffin, CarlClifford, Robert A.Turner, MarkPoston, RosanneHautzinger, KellyYeakey, AnneGirard, BethanyZhou, WenDeng, WeipingZhou, HonghongGhamloush, Sabine SchnyderKuter, Barbara J.Slobod, KarenMiller, Jacqueline M.Priddy, FrancesDas, Rituparna
- [50] Resiliency Engagement and Care in Health (REaCH): a telephone befriending intervention for upskilled rural youth in the context of COVID-19 pandemic-study protocol for a multi-centre cluster randomised controlled trialTRIALS, 2021, 22 (01)Devassy, Saju MadavanakaduAllagh, Komal PreetBenny, Anuja MariaScaria, LoraneCheguvera, NataniaSunirose, I. P.